• About
    • Leadership
  • Therapeutic Focus
    • UbiPro™ Platform
    • PROTAC
    • Therapeutic Areas
  • Partnering
    • The Progenra Advantage
    • Partnering Opportunities
    • Investor Relations
    • Collaborations
  • Careers
    • R&D, Biology
    • R&D, Medicinal Chemistry
  • News
    • News
    • Meetings
    • Publications
  • Blog

Ubiquitination and Cancer

by Progenra | May 14, 2019 | Blog

Abstract- Dynamic modulation and post-translational modification of proteins are tightly controlled biological processes that occur in response to physiological cues. One such dynamic modulation is ubiquitination, which marks proteins for degradation via the...
Next Entries »

Recent Posts

  • Progenra and the Frederick National Laboratory for Cancer Research Establish a contractor Cooperative Research and Development Agreement (cCRADA) to Develop KRAS Degraders for Cancer Therapy
  • Progenra receives funding from the Michael J Fox Foundation to develop Parkin activators to treat Parkinson’s disease.
  • Progenra Scientists publish a chapter in the ACS 2019 Medicinal Chemistry Reviews.
  • Characterization of Selective Covalent inhibitors of USP7- AACR Poster
  • Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs

Archives

  • February 2022
  • May 2020
  • May 2019
  • December 2018
  • April 2018
  • March 2018
  • September 2017
  • June 2017
  • May 2017
  • December 2016
  • December 2015
Progenra Logo

Contact

  610.644.6974
  610.644.8616
   271A Great Valley Parkway
      Malvern PA, 19355

For More Information

  info@progenra.com
  bd@progenra.com
      (Business Development inquries)
  • Facebook
  • Twitter
  • LinkedIn
© 2023 Progenra Inc. All Rights Reserved.
Website by eNet Web Services